Close Menu

NEW YORK – Diagnostic firm Veravas is developing a high-throughput antigen test for SARS-Cov-2 detection, along with a quantitative serology test for the virus that it plans to offer to support vaccine development and vaccine effectiveness testing.

The Charleston, South Carolina-based firm is applying its sample prep technology along with antibody technology licensed from Swedish antibody firm Vicunab AB to develop the tests, which it plans to launch within the next few months.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.